MorphoSys AG (MOR): Price and Financial Metrics

MorphoSys AG (MOR)

Today's Latest Price: $32.18 USD

0.00 (0.00%)

Updated May 28 8:00pm

Add MOR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MOR Stock Summary

  • MorphoSys AG's stock had its IPO on April 19, 2018, making it an older stock than merely 5.41% of US equities in our set.
  • With a price/sales ratio of 57.12, MorphoSys AG has a higher such ratio than 96.72% of stocks in our set.
  • With a year-over-year growth in debt of 59,422.91%, MorphoSys AG's debt growth rate surpasses 99.86% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MorphoSys AG are XNET, EGAN, AGYS, WIX, and GLPG.
  • Visit MOR's SEC page to see the company's official filings. To visit the company's web site, go to
MOR Daily Price Range
MOR 52-Week Price Range

MOR Stock Price Chart More Charts

MOR Price/Volume Stats

Current price $32.18 52-week high $37.96
Prev. close $32.18 52-week low $18.21
Day low $32.18 Volume 77,300
Day high $32.78 Avg. volume 134,466
50-day MA $26.89 Dividend yield N/A
200-day MA $29.25 Market Cap 4.23B

MorphoSys AG (MOR) Company Bio

MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.

MOR Latest News Stream

Event/TimeNews Detail
Loading, please wait...

MOR Latest Social Stream

Loading social stream, please wait...

View Full MOR Social Stream

Latest MOR News From Around the Web

Below are the latest news stories about MorphoSys AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.

MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab

MUNICH, GERMANY / ACCESSWIRE / May 20, 2020 / MorphoSys AG (MOR.F) Prime Standard Segment; MDAX & TecDAX; (MOR) and Incyte (INCY) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), including DLBCL arising from low grade lymphoma, who are not candidates for autologous stem cell transplantation (ASCT).

Yahoo | May 20, 2020

MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 14, 2020 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announced today that multiple abstracts from the Company's tafasitamab program ...

Yahoo | May 14, 2020

MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL

New two-year follow-up data (November 30, 2019 cut-off) of L-MIND trial corroborate previously reported primary analysis Updated IRC efficacy outcomes include objective response rate (ORR) of 58.8%, complete ...

Yahoo | May 14, 2020

MorphoSys AG (MOR) Q1 2020 Earnings Call Transcript

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR)Q1 2020 Earnings CallMay 9, 2020, 8:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, welcome to MorphoSys First Quarter 2020 Results Conference Call.

Yahoo | May 9, 2020

Do Its Financials Have Any Role To Play In Driving MorphoSys AG's (ETR:MOR) Stock Up Recently?

MorphoSys (ETR:MOR) has had a great run on the share market with its stock up by a significant 24% over the last...

Yahoo | May 9, 2020

Read More 'MOR' Stories Here

MOR Price Returns

1-mo 19.32%
3-mo 20.57%
6-mo 5.09%
1-year 31.40%
3-year N/A
5-year N/A
YTD -9.78%
2019 40.99%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching MOR

Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:

MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9383 seconds.